STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Scienture Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Scienture Holdings (SCNX) reported stockholder voting results from its 2025 Annual Meeting. A quorum was present with 10,990,183 votes representing 52.01% of the 21,132,260 shares of common stock entitled to vote.

All five director nominees were elected. Stockholders rejected increasing authorized shares to 2,000,000,000 common and 200,000,000 preferred. They approved increasing the 2019 equity plan reserve from 5,000,000 to 25,000,000 shares, a potential future offering that could exceed 20% of currently outstanding shares at a price below the Nasdaq “minimum price” under Rule 5635(d), and granting the Board discretion to effect a reverse stock split in a range of one‑for‑two to one‑for‑fifty. An adjournment proposal was approved but not used.

These approvals provide flexibility for potential capital transactions and share structure adjustments, while the failure to expand authorized share capital preserves current authorization levels.

Positive
  • None.
Negative
  • None.

Insights

Shareholders approved flexibility for issuance and reverse split; no authorized share increase.

Approval under Nasdaq Rule 5635(d) permits a potential offering exceeding 20% of outstanding common stock at a price below the “minimum price,” if pursued. This broadens potential financing methods without specifying timing or terms. Reverse split authority from one‑for‑two up to one‑for‑fifty gives the Board tools to adjust per‑share price and share count mechanics if needed.

The authorized share increase to 2,000,000,000 common and 200,000,000 preferred was not approved, limiting new authorization capacity. However, the 2019 Plan increase to 25,000,000 shares was approved, supporting equity compensation. Actual impact depends on future Board actions and market conditions.

false 0001382574 0001382574 2025-11-12 2025-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 12, 2025

 

SCIENTURE HOLDINGS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   001-39199   46-3673928

(State or other jurisdiction

of incorporation)

 

(Commission

File No.)

 

(I.R.S. Employer

Identification No.)

 

20 Austin Blvd.
Commack, NY 11725
(Address of Principal Executive Offices)

 

(631) 670-6039
(Registrant’s Telephone Number)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.00001 per share   SCNX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

Scienture Holdings, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders both (the “Annual Meeting”) virtually via a live webcast on November 12, 2025. The Company’s stockholders voted on six proposals at the Annual Meeting, each of which is listed below and described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 24, 2025. With respect to each proposal, holders of the Company’s common stock, par value $0.00001 (the “Common Stock”) were entitled to cast one vote per share of Common Stock held as of the close of business on the record date of September 25, 2025. At the beginning of the Annual Meeting, holders of Common Stock representing 10,990,183 votes were represented in person or by proxy at the Annual Meeting, which represented 52.01% of the voting power of the 21,132,260 shares of Common Stock entitled to vote at the Annual Meeting and constituted a quorum for the transaction of business.

 

At the Annual Meeting, the Company’s stockholders voted on the following proposals:

 

  1. To elect five directors to the Company’s board of directors (the “Board”), each to serve a term of one year and until their respective successors have been elected and qualified, or until their earlier resignation or removal;

 

  2. To consider and approve an Amendment to the Second Amended and Restated Certificate of Incorporation (the “Charter”) to increase the number of shares of Common Stock, authorized for issuance from 100,000,000 shares to 2,000,000,000 shares and of preferred stock, $0.00001 par value per share (the “Preferred Stock”), authorized for issuance from 10,000,000 shares to 200,000,000 shares;

 

  3. To consider and approve an Amendment to the Second Amended and Restated 2019 Equity Incentive Plan (the “2019 Plan”) to increase the number of shares of Common Stock available for issuance under the 2019 Plan from 5,000,000 shares to 25,000,000 shares;

 

  4. To consider and approve a potential future offering of Common Stock, which could result in the issuance of more than 20% of the currently outstanding shares of Common Stock at a price below the “minimum price,” as defined by, and in accordance with, Nasdaq Listing Rule 5635(d);
     
 

5.

 

To consider and vote on a proposal to grant the Board the discretion to amend the Charter to effect a reverse stock split at a ratio of not less than one-for-two and not greater than one-for-fifty, with the exact ratio to be set within that range at the discretion of the Board without further approval or authorization of the stockholders; and
     
  6. To approve an adjournment of the Annual Meeting, if necessary and appropriate, as determined by the Board in its sole discretion, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve the presented proposals or to constitute a quorum.

 

The final results of voting on each of the proposals presented at the Annual Meeting, as certified by the Company’s independent inspector of election, are set forth below.

 

 

 

 

Proposal No. 1: Election of Directors.

 

The stockholders elected each of the five director nominees to serve on the Board until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier resignation or removal. The results of the vote taken were as follows:

Nominee  Votes For   Votes Against   Abstentions   Broker Non-
Votes
 
Mayur Doshi   9,875,664    952,915         -    161,604 
Donald G. Fell   9,491,711    1,336,868    -    161,604 
Shankar Hariharan   10,714,392    114,187    -    161,604 
Subbarao Jayanthi   9,517,166    1,311,413    -    161,604 
Narasimhan Mani   9,959,634    868,945    -    161,604 

 

Proposal No. 2: Approval of the Amendment to the Charter to increase the number of shares of Common Stock, authorized for issuance from 100,000,000 shares to 2,000,000,000 shares and of Preferred Stock, authorized for issuance from 10,000,000 shares to 200,000,000 shares.

 

The stockholders of the Company rejected the amendment to the Charter to increase the number of shares of Common Stock, authorized for issuance from 100,000,000 shares to 2,000,000,000 shares and of Preferred Stock, authorized for issuance from 10,000,000 shares to 200,000,000 shares. The results of the vote taken were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
5,326,576   5,501,986   17   161,604

 

Proposal No. 3: Approval of the Amendment to the 2019 Plan to increase the number of shares of Common Stock available for issuance thereunder from 5,000,000 shares to 25,000,000 shares.

 

The stockholders of the Company approved the amendment to the 2019 Plan to increase the number of shares of Common Stock available for issuance from 5,000,000 shares to 25,000,000 shares. The results of the vote taken were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
5,599,253   5,229,326   -   161,604

 

Proposal No. 4: Approval of a potential future offering of Common Stock, which could result in the issuance of more than 20% of the currently outstanding shares of Common Stock at a price below the “minimum price,” as defined by, and in accordance with, Nasdaq Listing Rule 5635(d).

 

The stockholders of the Company approved the proposal of a potential future offering of Common Stock, which could result in the issuance of more than 20% of the currently outstanding shares of Common Stock at a price below the “minimum price,” as defined by, and in accordance with, Nasdaq Listing Rule 5635(d). The results of the vote taken were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
5,607,934   5,220,045   600   161,604

 

Proposal No. 5: Approval to grant the Board the discretion to amend the Charter to effect a reverse stock split at a ratio of not less than one-for-two and not greater than one-for-fifty, with the exact ratio to be set within that range at the discretion of the Board without further approval or authorization of the stockholders.

 

The stockholders of the Company approved the proposal to grant the Board the discretion to amend the Charter to effect a reverse stock split at a ratio of not less than one-for-two and not greater than one-for-fifty, with the exact ratio to be set within that range at the discretion of the Board without further approval or authorization of the stockholders. The results of the vote taken were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
6,276,243   4,713,433   507   -

 

Proposal No. 6: Approval of an adjournment of the Annual Meeting, if necessary and appropriate, as determined by the Board in its sole discretion, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve the presented proposals or to constitute a quorum.

 

The stockholders of the Company approved the proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies if there were insufficient votes to approve the presented proposals or to constitute a quorum. Although this proposal was approved by the Company’s stockholders, because there was a quorum present and there were sufficient votes represented at the time of the Annual Meeting to approve the proposals, adjournment of the Annual Meeting was deemed unnecessary. The results of the vote taken were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
9,616,062   1,343,481   30,640  

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SCIENTURE HOLDINGS, INC.
     
  By: /s/ Dr. Narasimhan Mani
    Dr. Narasimhan Mani
    Co-Chief Executive Officer
     
Date: November 14, 2025    

 

 

FAQ

What did SCNX shareholders approve regarding potential stock issuance?

They approved a potential future offering that could exceed 20% of currently outstanding common shares at a price below the Nasdaq “minimum price” under Rule 5635(d).

Did SCNX approve an increase in authorized share capital?

No. Stockholders rejected increasing authorized common shares to 2,000,000,000 and preferred shares to 200,000,000.

What reverse stock split authority did SCNX obtain?

Stockholders granted the Board discretion to effect a reverse split between 1-for-2 and 1-for-50 without further stockholder approval.

What changes were approved to the 2019 equity plan?

The share reserve was increased from 5,000,000 to 25,000,000 shares of common stock.

Was there a quorum at the SCNX Annual Meeting?

Yes. 10,990,183 votes were represented, equal to 52.01% of the 21,132,260 shares entitled to vote.

Were directors elected at the meeting?

Yes. All five nominees were elected to serve until the next annual meeting and until successors are duly elected and qualified.

Was the adjournment proposal used?

No. Although approved, adjournment was unnecessary because a quorum existed and sufficient votes were present.
Scienture Holdings, Inc

NASDAQ:SCNX

SCNX Rankings

SCNX Latest News

SCNX Latest SEC Filings

SCNX Stock Data

23.87M
32.72M
25.78%
1.56%
0.67%
Pharmaceutical Retailers
Pharmaceutical Preparations
Link
United States
COMMACK